非小细胞肺癌老年患者一线采用小剂量口服长春瑞滨单药化疗的安全性
Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.
作者信息
Mencoboni Manlio, Filiberti Rosa Angela, Taveggia Paola, Del Corso Lisette, Del Conte Alessandro, Covesnon Maria Grazia, Puccetti Cheti, Donati Sara, Auriati Laura, Amoroso Domenico, Camerini Andrea
机构信息
Oncology Unit, Villa Scassi Hospital, Genoa, Italy
Clinical Epidemiology, IRCCS AOU San Martino-IST-National Cancer Research Institute, Genoa, Italy.
出版信息
Anticancer Res. 2017 Jun;37(6):3189-3194. doi: 10.21873/anticanres.11679.
BACKGROUND/AIM: The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall survival were secondary end-points.
PATIENTS AND METHODS
Seventy-six patients received 50 mg of oral vinorelbine three times per week, until disease progression, patient refusal or unacceptable toxicity. Patients were evaluated for response and toxicity after one cycle of chemotherapy. The treatment was considered feasible with a grade 3/4 toxicity rate lower than 20%.
RESULTS
Clinical benefit was observed in 50% of patients. Median overall survival was 8.0 months. Grade 1/2 toxicity was observed in 53 patients (69.7%), grade 3 toxicity in eight patients (10.5%). One patient had grade 4 diarrhea.
CONCLUSION
Metronomic oral vinorelbine is safe in elderly patients, allowing for long-term disease stabilization with optimal patient compliance.
背景/目的：节拍性长春瑞滨的最佳治疗用途尚未明确。我们旨在评估节拍性口服长春瑞滨用于一线治疗不适宜接受多药化疗的老年晚期肺癌患者的安全性。无进展生存期、缓解率和总生存期为次要终点。
患者与方法
76例患者每周口服长春瑞滨50mg，每日3次，直至疾病进展、患者拒绝或出现不可接受的毒性反应。化疗1个周期后评估患者的缓解情况和毒性反应。若3/4级毒性反应发生率低于20%，则认为该治疗可行。
结果
50%的患者观察到临床获益。中位总生存期为8.0个月。53例患者（69.7%）出现1/2级毒性反应，8例患者（10.5%）出现3级毒性反应。1例患者出现4级腹泻。
结论
节拍性口服长春瑞滨对老年患者安全，可实现疾病长期稳定，患者依从性良好。
Zotero 插件